Inhibition of tumor suppressor Protein Phosphatase 2A (PP2A) has been denoted as one of the minimal requirements for malignant transformation of a human cell. In Read more
A New Mechanism of Stress-Induced Transcriptional Memory In a long-term project in the Sistonen Laboratory, led by Anniina Vihervaara in collaboration with John T. Lis Read more
BioCity Turku opens a call for research funding for all BioCity Turku research groups. The applied funding is intended for new openings promoting research on emerging topics Read more
Professor Laura Elo’s research group is involved in the extensive European Network Linking Informatics and Genomics of Helper T cells (ENLIGHT-TEN+). The aim of the Read more
BioCity Turku continues the Frontiers of Science seminar series online as eTALKs during the spring 2021. The seminars are meant for both researchers and students Read more
After his Ph.D. studies at University of Turku, Tapio carried out his postdoc in the laboratory of Sarah Teichmann, Wellcome Trust Sanger Institute. Prior to Read more
After his M.D. and Ph.D. studies at University of Turku, Otto has carried out his postdoc in University of Cambridge, UK, Karolinska Institutet and University Read more
. In the context of the 30th BioCity Symposium (19th–20th August 2021), the seventeenth Elias Tillandz prize will be awarded for the best life science Read more
Congratulations! Klaus Elenius has been elected Chairman of the Finnish Medical Society. Article in Finnish Klaus Elenius Lääketieteen Seuran johtoon – ”Tutkimus ei ole tällä Read more
The Academy of Finland Flagship Programme, Innovation Ecosystem Based on the Immune System, InFLAMES awarded fixed-term group leader positions to Dr. Tapio Lönnberg and Read more
The research groups of Lea Sistonen & John E. Eriksson receive 968.000 € for a research project to specifically target HPV-Driven Cancers Human papillomavirus Read more
Last updated on June 25, 2025
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
